CSCC Webinar Lectureship on Critical Care Medicine  

Thursday March 22, 2018 

11:00 PT / 12:00 MT / 13:00 CT / 14:00 ET / 15:00 AT / 16:00 NL

Sponsored by

Roche logo

 

Procalcitonin: Should your hospital use it?

Speaker: 

Mark Downing
Head of Infectious Diseases and Antimicrobial Stewardship Officer
 Saint Joseph's Health Centre, Toronto

 

Procalcitonin has been studied extensively as a biomarker for bacterial infections, in particular pneumonia and sepsis. Some randomized controltrials and meta-analyses suggest that procalcitonin-guided care can reduce antimicrobial use and even patient mortality. Some current guidelines recommend its routine use as part of antimicrobial stewardship programs and in clinical decision making for certain infections. However there still exists some controversy over procalcitonin's clinical utility, especially in the'real world'.

At the conclusion of this session, participants will be able to:
(1)  Understand how procalcitonin can guide clinical decision making for patients with suspected bacterial infections
(2)  Understand what may cause a false positive and false negative result
(3)  Understand the evidence for using procalcitonin to guide therapy in sepsis and respiratory tract infections
(4)  Understand the limitations of using procalcitonin in the'real world'

Mark Downing is the Head of lnfectious Diseases and Medical Director of the Antimicrobial-Stewardship Program at Saint Joseph's Health Centre in Toronto. He completed his medical degree at Dalhousie University, followed by lnternal Medicine at the University of Ottawa and a fellowship in lnfectious Diseases at the University of Toronto. He is also a graduate of the Rotman School of Management Advancei Health Leadership Program. His primary interests include innovating within the field of antimicrobial stewardship and developing collaborations with multidisciplinary teams to provide the best care for patients with infections. 

There is no charge to attend this lecture but it is necessary to register  

 

 

 

CSCC Webinar Lectureship on Critical Care Medicine
Thursday March 22, 2018
1100 PT / 1200 MT / 1300 CT / 1400 ET / 1500 AT / 1600 NL

Sponsored by Roche

Procalcitonin: Should your hospital use it?
Speaker: Mark Downing
, Head of Infectious Diseases and Antimicrobial Stewardship Officer, Saint Joseph's Health Centre, Toronto

Procalcitonin has been studied extensively as a biomarker for bacterial infections, in particular pneumonia and sepsis. Some randomized controltrials and meta-analyses suggest that procalcitonin-guided care can reduce antimicrobial use and even patient mortality. Some current guidelines recommend its routine use as part of antimicrobial stewardship programs and in clinical decision making for certain infections. However there still exists some controversy over procalcitonin's clinical utility, especially in the'real world'.

At the conclusion of this session, participants will be able to:

  • Understand how procalcitonin can guide clinical decision making for patients with suspected bacterial infections.
  • Understand what may cause a false positive and false negative result.
  • Understand the evidence for using procalcitonin to guide therapy in sepsis and respiratory tract infections.
  • Understand the limitations of using procalcitonin in the'real world'.

Mark Downing is the Head of lnfectious Diseases and Medical Director of the Antimicrobial-Stewardship Program at Saint Joseph's Health Centre in Toronto. He completed his medical degree at Dalhousie University, followed by lnternal Medicine at the University of Ottawa and a fellowship in lnfectious Diseases at the University of Toronto. He is also a graduate of the Rotman School of Management Advancei Health Leadership Program. His primary interests include innovating within the field of antimicrobial stewardship and developing collaborations with multidisciplinary teams to provide the best care for patients with infections.

REGISTRANT DETAILS

First Name:
Last Name:
E-mail:*
No of Participants*

GROUP DETAILS

Number of participants in group:*
Are you the Group contact person?*
Group Contact Person*
Group Contact Email:*
(This email address will receive the slides and teleconference details)

Assistance*
Word Verification: